Background Despite the availability of effective drug therapies that reduce low‐density
lipoprotein (LDL)‐cholesterol (LDL‐C), cardiovascular disease (CVD) remains an important …

Aims We performed a network meta-analysis of randomized controlled trials (RCTs) in
patients with primary hypercholesterolaemia to compare the impact of proprotein convertase …

Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to the low-density lipoprotein
receptor, escorting it to its destruction in the lysosome and thereby preventing the …

The proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising
treatment target to lower serum cholesterol, a major risk factor of cardiovascular diseases …

BACKGROUND: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a
new class of cholesterol-lowering medications that provide significant reductions in lipids but …

Abstract Purpose of Review The purpose of this article is to review current evidence for
lipoprotein (a)(Lp (a)) as a risk factor for multiple cardiovascular (CV) disease phenotypes …

A report from panel members appointed to the Eighth Joint National Committee titled “2014
Evidence-Based Guideline for the Management of High Blood Pressure in Adults” has …

Monoclonal antibodies (MAb's) have become one the most powerful therapeutic and
diagnostic tools in modern medicine. Some estimates target the worldwide market of MAb's …

Proprotein convertase subtilisin kexin type 9 (PCSK9) belongs to the proprotein convertase
family. Several studies have demonstrated its involvement in the regulation of low-density …

Context Limited information was available on detailed associations of low-density
lipoprotein cholesterol (LDL-C) with all-cause and cause-specific mortality in older adults …